A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Recruiting now · Phase 2
Conditions studied: Multiple Myeloma
In brief
The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body, typically through chemotherapy), or an alternative administration of cilta-cel infusion following a cyclophosphamide and fludarabine lymphodepletion regimen.
Key facts
- Study ID
- NCT07149857
- Run by
- Janssen Research & Development, LLC
- People needed
- 60
- Starts
- 2025-10-03
- Expected to finish
- 2029-04-06
- Last updated by the study team
- 2026-07-06
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Documented diagnosis of newly diagnosed multiple myeloma (NDMM) according to the most recent international myeloma working group (IMWG) diagnostic criteria and measurable disease at diagnosis (prior to start of any anti-myeloma therapy): Serum monoclonal paraprotein (M-protein) level greater than equal to (>=)1.0 grams per deciliter (g/dL) or urine M-protein level >= 200 milligrams (mg)/24 hours; or light chain multiple myeloma in whom the only measurable disease is by serum free light chain (FLC) levels in the serum: involved serum free light chain >= 10 mg/dL and abnormal serum free light chain ratio
- Not considered a candidate for high-dose chemotherapy with stem cell transplantation due to: (a) Advanced age; or (b) Presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with stem cell transplantation; or (c) Participant refusal of high-dose chemotherapy with stem cell transplantation as initial treatment
- Participant must have received at least 3 cycles and no more than 5 cycles of induction therapy. Initially, only participants receiving triplet induction therapy with DRd or VRd will be enrolled. Only after sponsor notification, participants receiving quadruplet DVRd induction therapy may be enrolled (screening can commence as early as during Cycle 3 of induction). Participants must have achieved >= partial response (PR) on the most recent disease assessment to be enrolled
- Eastern cooperative oncology group (ECOG) Performance Status score of 0 or 1
- Must be willing and able to adhere to the lifestyle restrictions specified in the protocol
You may not qualify if…
- Frailty index of >= 2 according to Myeloma Geriatric Assessment score
- Known allergies, hypersensitivity, or intolerance to study intervention or its active agents
- Grade 2 or higher ongoing non-hematologic toxicity due to induction therapy, with the exception of grade 2 peripheral neuropathy due to bortezomib
- Participants who require continuous supplemental oxygen
Where it is running
- Hosp. Virgen Del Rocio — Seville, Spain (enrolling)
- Hosp Clinico Univ de Salamanca — Salamanca, Spain (enrolling)
- Hosp. Univ. Marques de Valdecilla — Santander, Spain (enrolling)
- University of California San Francisco — San Francisco, California, United States (enrolling)
- Cleveland Clinic — Cleveland, Ohio, United States (enrolling)
- Royal Prince Alfred Hospital — Camperdown, Australia (enrolling)
- Austin Hospital — Heidelberg, Australia (enrolling)
- Fiona Stanley Hospital — Murdoch, Australia (enrolling)
- Princess Alexandra Hospital — Woolloongabba, Australia (enrolling)
- Hosp. Univ. Germans Trias I Pujol — Badalona, Spain (enrolling)
- Hosp Univ Vall D Hebron — Barcelona, Spain (enrolling)
- Hosp. Clinic de Barcelona — Barcelona, Spain (enrolling)
- Hosp. Univ. 12 de Octubre — Madrid, Spain (enrolling)
- Clinica Univ. de Navarra — Pamplona, Spain (enrolling)
- Moffitt Cancer Center — Tampa, Florida, United States
- University of Iowa Hospital and Clinics — Iowa City, Iowa, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.